US Patent

US8663683 — Sustained-release formulations of topiramate

Method of Use · Assigned to Supernus Pharmaceuticals Inc · Expires 2027-11-16 · 1y remaining

Vulnerability score 80/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects sustained-release formulations of topiramate for once-a-day oral administration to treat or prevent pathological disorders in mammalian subjects.

USPTO Abstract

Pharmaceutical compositions of topiramate for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the compositions of which can be selectively adjusted, respectively, to release the active ingredient along a pre-determined release profile. Method of treating or preventing pathological disorders in mammalian subjects comprising the administration of the novel formulations disclosed herein is also provided.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-106 — Topamax
U-106 — Topamax
U-1992 — Topamax
U-1992 — Topamax

Patent Metadata

Patent number
US8663683
Jurisdiction
US
Classification
Method of Use
Expires
2027-11-16
Drug substance claim
No
Drug product claim
Yes
Assignee
Supernus Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.